Home >> Tag Archives: Loxo Oncology—

Tag Archives: Loxo Oncology—

FDA approves larotrectinib

February 2019—The FDA granted accelerated approval to larotrectinib (Vitrakvi, Loxo Oncology) for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation, are metastatic, or where surgical resection is likely to result in severe morbidity and have no satisfactory alternative treatments or that have progressed following treatment.

Read More »